CLINICAL-EVALUATION OF KETOROLAC TROMETHAMINE 0.5-PERCENT OPHTHALMIC SOLUTION FOR THE TREATMENT OF SEASONAL ALLERGIC CONJUNCTIVITIS

We evaluated 148 patients with allergic conjunctivitis in a double-mas ked, paired comparison clinical trial comparing ketorolac 0.5% ophthal mic solution with vehicle. Patients received one drop of each study me dication in preassigned eyes, four times a day, for seven days. Both t reatments showed significant changes from baseline in the signs and sy mptoms associated with allergic conjunctivitis. Evaluations at the fin al visit (day 7 or 8) showed that ketorolac-treated eyes had a signifi cant treatment response when compared to vehicle-treated eyes for conj unctival inflammation (p = 0.010), ocular itching (p = 0.006), swollen eyes (p = 0.002), discharge/tearing (p = 0.021), foreign body sensati on (p = 0.035), and conjunctival injection (p = 0.016). Mean scores ev aluating the overall therapeutic effect of the study treatments at the completion of the study were higher for ketorolac-treated eyes than f or vehicle-treated eyes as rated by investigators (p = 0.004) and stud y patients (p < 0.001). Results of this study confirmed the trends of a previous study showing that ketorolac 0.5% ophthalmic solution appli ed topically is an effective therapy for allergic conjunctivitis.